Status and phase
Conditions
Treatments
About
This is a non-randomized, open-label, single-dose study to evaluate the pharmacokinetics (PK) of uprifosbuvir (MK-3682), the M5 and M6 metabolites of uprifosbuvir, and ruzasvir (MK-8408), in participants with moderate hepatic insufficiency (HI), participants with severe HI, and age-matched healthy control participants.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
HI Participants Only:
All Participants:
Exclusion criteria
HI Participants Only:
Healthy Participants Only:
All Participants:
Primary purpose
Allocation
Interventional model
Masking
24 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal